Bruce E. Sands, MD, MS, is the Dr. Burrill B. Crohn Professor of Medicine at Mount Sinai Hospital in New York. He joined Mount Sinai in 2010 as chief of the Henry D. Janowitz Division of Gastroenterology. Before coming to Mount Sinai, he was medical co-director of the Crohn's & Colitis Center and acting chief of the gastrointestinal unit at Massachusetts General Hospital in Boston.
Dr. Sands is chair of the Clinical Research Alliance of the Crohn's Foundation of America and chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. He was named humanitarian of the year by the New England Chapter of the Crohn's and Colitis Foundation of America. He is an associate editor for Gastroenterology.
Dr. Sands was among the first to report the efficacy of infliximab — a drug used to treat autoimmune diseases — in ulcerative colitis, which was later confirmed in multicenter, randomized, controlled trials. He was also principal investigator of the international ACCENT II study, which demonstrated the efficacy of infliximab as a long-term treatment for fistulizing Crohn's disease. His research includes the creation of a population-based cohort of IBD in Rhode Island, a project that is being funded by the National Institute of Health and the CDC.
Dr. Sands earned his medical degree at Boston University School of Medicine in and completed his residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. He completed clinical and research fellowships at Massachusetts General Hospital. He also earned a Master of Science degree in epidemiology at Harvard School of Public Health.